Exhibit 99.1


                  Opexa Shares to Trade on NASDAQ Global Market


     THE WOODLANDS, Texas--(BUSINESS WIRE)--Sept. 1, 2006--Opexa Therapeutics,
Inc. (NASDAQ:OPXA), a company involved in the development and commercialization
of cell therapies, today announced that its common shares will be listed and
begin trading today on the NASDAQ Global Market. The Company's trading symbol,
OPXA, will remain unchanged. Opexa's common shares will no longer be listed on
the OTC Bulletin Board.

     David B. McWilliams, chief executive officer of Opexa, commented, "We
believe that this NASDAQ listing will afford us increased visibility within the
investment community, while enhancing the trading liquidity of Opexa's shares.
This is an important achievement and milestone for the Company, and is part of
our ongoing efforts to maximize shareholder value."

     About Opexa Therapeutics

     Opexa Therapeutics develops and commercializes cell therapies to treat
several major disease areas such as MS, rheumatoid arthritis, pancreatic and
cardiac conditions. Opexa has exclusive license from Baylor College of Medicine
for individualized cell therapies and has initiated a Phase IIb clinical trial
to evaluate effectiveness in treating MS. The Company holds the exclusive
worldwide license for an autologous T cell vaccine for rheumatoid arthritis from
the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences of
the People's Republic of China. Opexa also holds the exclusive worldwide license
from the University of Chicago, through its prime contractor relationship with
Argonne National Laboratory, for patents relating to the use of adult
pluripotent stem cells derived from patients' own circulating blood. For more
information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

     Safe Harbor Statement

     This press release contains "forward-looking statements," including
statements about Opexa Therapeutics' growth and future operating results,
discovery and development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or information.
These forward-looking statements are based on management's current assumptions
and expectations and involve risks, uncertainties and other important factors,
specifically including those relating to Opexa Therapeutics' ability to obtain
additional funding, develop its stem cell technologies, achieve its operational
objectives, and obtain patent protection for its discoveries, that may cause
Opexa Therapeutics' actual results to be materially different from any future
results expressed or implied by such forward-looking statements. Opexa
Therapeutics undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information, future
events or otherwise.


     CONTACT: Opexa Therapeutics, Inc.
              Lynne Hohlfeld, 281-719-3421
              lhohlfeld@opexatherapeutics.com
              or
              Investor Relations:
              Lippert/Heilshorn & Associates
              Kim Sutton Golodetz, 212-838-3777
              kgolodetz@lhai.com
              or
              Bruce Voss, 310-691-7100
              bvoss@lhai.com